J&J Will Turn To Clinical Evidence To Overcome Reimbursement Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
Reimbursement challenges in 2005 slowed adoption of Johnson & Johnson's injectable extended-release antipsychotic Risperdal Consta, the company reported Jan. 24
You may also be interested in...
J&J Submits Paliperidone ER
Johnson & Johnson submitted an NDA Nov. 29 for its Risperdal follow-on paliperidone extended-release, the firm said Nov. 30
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.